|Bid||9.67 x 1000|
|Ask||9.75 x 4000|
|Day's Range||9.66 - 9.83|
|52 Week Range||8.24 - 13.30|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 27, 2017|
|1y Target Est||11.47|
AMSTERDAM, October 13, 2021--Teva Pharmaceuticals Europe BV, a European affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital – Katholisches Klinikum Bochum (Bochum, Germany), presented today at ECTRIMS congress new analyses of the COBRA study, a real-world evidence study on the safety of COPAXONE® (glatiramer acetate or GA) used by mothers with multiple sclerosis (MS) during pregnancy and breastfeeding.
If you've ever wondered why Wall Street and retail investors pay such close attention to billionaire Warren Buffett, it's because he has an impeccable moneymaking track record. Since taking over as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, the Oracle of Omaha has overseen the creation of nearly $600 billion in market value for shareholders, and delivered an average annual return of 20% for the company's Class A shares. Riding Buffett's coattails has long been a profitable venture.
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has temporarily stopped drug production at its Irvine plant in California to address issues raised by the FDA after a recent inspection. The Company did not specify the issues raised by the agency. Bloomberg reported that the production halt followed Teva's recall of more than 2.5 million vials of drugs in recent months, many of them cancer medications. The report said the vials might have been contaminated with mold owing to water leaks discovered